Proceedings of ICBioMed 2025 Symposium: AI for Healthcare: Advanced Medical Data Analytics and Smart Rehabilitation
DOI: 10.54254/2753-8818/2025.AU25169

The Mechanism and Treatment Methods of Glutathione Levels in Reducing Autism Spectrum Disorder

Xuyang Zhang

School of Shanghai Jin Qiu, Shanghai, China
zxuyang244@outlook.com

Abstract. Autism spectrum disorder (ASD) is a neurodevelopmental condition associated with oxidative stress and problems in the antioxidant system, so the aim of this study was to figure out how glutathione (GSH) could lessen ASD symptoms and evaluate treatment methods related to GSH, thus an integrative review of 11 peer - reviewed studies was carried out to combine mechanistic understandings and therapeutic proof, and central mechanisms included the antioxidant and neuroprotective characteristics of GSH, its regulation of neurotransmitters like glutamate, and its part in gene - environment interactions influencing ASD vulnerability, while examined interventions covered N - acetylcysteine (NAC) supplementation and new biotherapies, and clinical results showed slight improvements in social behavior and reductions in repetitive behaviors, and it was found that GSH levels were considerably lower in people with ASD, which corresponded with higher oxidative stress biomarkers and neuroinflammation, additionally GSH was proven to reduce excitotoxicity, boost synaptic plasticity, and control epigenetic pathways involved in neurodevelopment, however despite these encouraging outcomes, differences in treatment reactions and inadequate long - term safety information remained major drawbacks, in short, GSH turned out to be a possible therapeutic target for ASD and antioxidant - based interventions might enhance traditional treatments, but establishing standardized dosing rules and conducting large - scale randomized controlled trials were crucial to confirm their effectiveness and safety for clinical use.

Keywords: Autism Spectrum Disorder (ASD), Glutathione (GSH), Oxidative Stress, Antioxidant Therapy, Neuroprotection.

1. Introduction

Autism Spectrum Disorder (ASD) is a developmental disorder marked by difficulties in social interaction, communication impairments, and repetitive patterns of behavior, with symptoms varying in severity. Over recent decades, the incidence of ASD has increased significantly, prompting deeper inquiry into its multifactorial causes—including genetic predispositions, environmental exposures, and biochemical abnormalities. Among these, oxidative stress has been increasingly recognized as a core contributor to the disorder's pathophysiology, disturbing the redox equilibrium essential for neural function. In this context, glutathione (GSH), the most prevalent intracellular antioxidant, has emerged as a molecule of major interest.

© 2025 The Authors. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/).

DOI: 10.54254/2753-8818/2025.AU25169

Glutathione plays a vital role in maintaining cellular oxidative balance, detoxifying harmful metabolites, and modulating immune responses. Numerous studies have reported decreased levels of GSH and associated enzymatic activity in individuals with ASD, corresponding with elevated oxidative biomarkers and diminished cellular resilience. This redox imbalance has been linked to neural dysfunction and behavioral symptoms observed in ASD populations. However, existing research frequently isolates mechanistic insights from therapeutic application, creating a disconnect between understanding how GSH contributes to ASD pathology and how it can be targeted clinically. To bridge this divide, the current paper aims to investigate glutathione's multifaceted role in ASD and assess therapeutic strategies aimed at modulating GSH homeostasis.

This integrative review synthesizes recent findings on GSH's biochemical functions—such as its involvement in redox signaling, neurotransmitter regulation, mitochondrial integrity, and epigenetic processes—and evaluates a range of therapeutic approaches including precursor supplementation, antioxidant therapies, and novel delivery systems. By examining both underlying mechanisms and emerging clinical interventions, the paper seeks to identify promising directions for personalized treatment strategies. A better understanding of how GSH influences ASD may not only guide biomarker development and precision medicine but also support the incorporation of redox-focused therapies into broader, multidisciplinary care models for individuals on the spectrum.

2. ASD and oxidative stress

Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition marked by deficits in communication, social interaction, and restricted, repetitive behaviors. While the underlying causes of ASD are multifactorial, recent research has increasingly implicated oxidative stress as a major contributor to its development. Oxidative stress arises from an imbalance between reactive oxygen species (ROS) production and the body's antioxidant defenses. Elevated levels of ROS can damage proteins, lipids, and DNA, disrupting cellular function and neural integrity [1].

Multiple studies have found that children with ASD exhibit elevated markers of oxidative damage, such as increased lipid peroxidation and protein oxidation, alongside reduced antioxidant capacity. One of the most consistently reported abnormalities is decreased levels of glutathione (GSH), a vital component of the intracellular antioxidant system. The reduced ratio of GSH to its oxidized form (GSSG) in individuals with ASD is considered a reliable indicator of redox imbalance [2]. This biochemical disturbance has been observed in both plasma and brain tissue, with evidence of region-specific glutathione depletion in areas of the brain associated with cognition and emotion [3].

The origins of oxidative stress in ASD appear to be both genetic and environmental. Genetic polymorphisms affecting antioxidant enzymes, including glutathione S-transferases (GSTs), have been linked to increased susceptibility to oxidative damage in individuals with ASD [4]. At the same time, environmental exposures to toxins such as heavy metals or air pollutants can overwhelm the already compromised antioxidant systems in these individuals, exacerbating oxidative injury [5]. These findings support the hypothesis that gene-environment interactions play a key role in the redox imbalance observed in ASD.

Oxidative stress not only causes molecular damage but also contributes to immune dysregulation and neuroinflammation—both frequently observed in ASD patients. The accumulation of ROS can activate microglia and astrocytes, triggering pro-inflammatory cascades that further disrupt neuronal signaling and connectivity [6]. Additionally, oxidative stress has been shown to impair neurodevelopmental processes, including neurogenesis, synaptic plasticity, and mitochondrial function, all of which are critical for normal cognitive and behavioral development [7].

DOI: 10.54254/2753-8818/2025.AU25169

In summary, oxidative stress serves as a critical pathophysiological mechanism in ASD, linking genetic vulnerability and environmental exposure to neuronal dysfunction. Among the various antioxidant systems involved, glutathione appears particularly crucial, as its depletion strongly correlates with oxidative damage and symptom severity. This connection makes glutathione metabolism a promising focus for therapeutic intervention and further investigation in ASD research.

3. Glutathione function

Glutathione (GSH) is a tripeptide composed of glutamate, cysteine, and glycine, and it is the most abundant non-protein thiol in mammalian cells. It plays a significant role in maintaining intracellular redox balance by directly scavenging reactive oxygen species (ROS) and by serving as a cofactor in enzymatic antioxidant processes. GSH operates in both its reduced form (GSH) and its oxidized form (GSSG); the ratio between them is a sensitive indicator of cellular oxidative stress. Decreased GSH/GSSG ratios are consistently observed in individuals with autism spectrum disorder (ASD), indicating a compromised redox environment [8].

The synthesis of GSH occurs through a two-step enzymatic process involving γ-glutamylcysteine synthetase and glutathione synthetase. This pathway is tightly regulated by oxidative stress signals and cellular demand. Under oxidative conditions, GSH is rapidly consumed to neutralize ROS, and insufficient resynthesis can lead to sustained redox imbalance [9]. In ASD, studies have demonstrated both reduced GSH production and impaired recycling from GSSG, contributing to elevated oxidative stress and impaired detoxification capacity [10].

Beyond its role as a redox buffer, GSH contributes significantly to neuronal health. It protects mitochondrial integrity by preventing ROS-induced damage to mitochondrial membranes and enzymes. Since mitochondria are critical for neuronal energy supply and synaptic function, GSH deficiency can impair neural metabolism and plasticity [11]. Additionally, GSH is involved in the detoxification of heavy metals, which is relevant for ASD individuals who often exhibit impaired metal excretion and increased sensitivity to environmental toxins [12].

GSH also modulates key neurotransmitter systems. It influences glutamatergic, dopaminergic, and serotonergic pathways—systems that are frequently altered in ASD. GSH has been shown to regulate glutamate homeostasis, thereby impacting excitatory-inhibitory balance in the brain, a known factor in ASD pathophysiology [13]. Imbalances in these neurotransmitters can lead to behavioral and cognitive symptoms characteristic of ASD, including social withdrawal and repetitive behavior.

Furthermore, glutathione plays a key role in immune regulation. It modulates lymphocyte proliferation, cytokine secretion, and the function of natural killer cells. Given that many individuals with ASD exhibit immune abnormalities, GSH deficiency may contribute to or exacerbate immune dysfunction [14]. These combined roles in antioxidant defense, neurotransmission, and immune modulation underscore glutathione's central position in neurodevelopment and systemic homeostasis.

In conclusion, glutathione is far more than a passive antioxidant. It is a dynamic regulator of redox biology, neuronal stability, and immune competence. Its deficiency in individuals with ASD reveals both a biomarker of disease severity and a potential point of therapeutic intervention. Understanding and restoring GSH function is therefore essential to developing targeted treatments for autism spectrum disorder.

DOI: 10.54254/2753-8818/2025.AU25169

4. Mechanisms of action

The therapeutic relevance of glutathione (GSH) in autism spectrum disorder (ASD) is deeply rooted in its multifunctional biological actions. Beyond its well-established role as an antioxidant, GSH regulates neurotransmitter activity, maintains redox-dependent signaling, and influences gene-environment interactions. These mechanisms collectively explain why disrupted GSH metabolism is frequently observed in ASD and why restoring GSH levels has shown promise in clinical studies.

4.1. Antioxidant defense and mitochondrial protection

GSH plays a significant role in neutralizing reactive oxygen species (ROS) and reducing oxidative damage to cellular components. In ASD, heightened oxidative stress has been linked to lower GSH levels, which in turn impair mitochondrial membrane stability and function. Mitochondrial dysfunction contributes to abnormal synaptic activity and behavioral impairments seen in ASD [15]. By preserving mitochondrial redox balance, GSH supports energy metabolism and reduces neuronal apoptosis [16].

4.2. Neurotransmitter modulation

GSH also influences neurotransmission, particularly by regulating the glutamate–glutamine cycle. Excess glutamate can lead to excitotoxicity, which is associated with repetitive behaviors, anxiety, and sensory abnormalities in ASD. GSH helps buffer extracellular glutamate levels, thereby restoring excitatory-inhibitory balance in the brain [17]. Moreover, GSH modulates dopamine and serotonin synthesis by stabilizing redox-sensitive enzymes involved in monoamine production. Imbalances in these neurotransmitters may contribute to the social and emotional symptoms characteristic of ASD [18].

4.3. Methylation and epigenetic control

A less widely known but crucial function of GSH involves its participation in the methionine and transculturation pathways, which are vital for DNA methylation. In ASD individuals, decreased GSH availability disrupts the production of S-adenosylmethionine (SAM), an essential methyl donor, and causes accumulation of homocysteine—both of which are biomarkers of impaired methylation [19]. This disruption may lead to widespread epigenetic changes during brain development, potentially affecting gene expression patterns associated with neural connectivity and plasticity.

4.4. Detoxification and gene-environment interactions

GSH is integral to detoxification, especially in conjugating xenobiotics and heavy metals. Genetic polymorphisms in glutathione-S-transferase enzymes (e.g., GSTM1 and GSTP1) can impair detoxification efficiency and are associated with increased vulnerability to oxidative damage in ASD populations [20]. Such genetic susceptibilities, when combined with environmental exposures like mercury or lead, may exacerbate ASD severity. Therefore, GSH functions as a buffer between genetic risk and environmental insult, reinforcing its role in the gene-environment interplay that characterizes ASD etiology.

In conclusion, glutathione's impact in ASD extends far beyond antioxidant buffering. It actively modulates neurotransmitters, sustains mitochondrial function, regulates methylation-dependent gene

DOI: 10.54254/2753-8818/2025.AU25169

expression, and facilitates detoxification processes. These diverse mechanisms explain both the pathology associated with GSH deficiency and the rationale for GSH-based interventions in treating ASD.

5. Treatment approaches

Given the strong correlation between glutathione (GSH) deficiency and autism spectrum disorder (ASD), numerous therapeutic strategies have been explored to restore GSH levels and improve clinical symptoms. These approaches include direct GSH supplementation, precursor-based nutritional support, targeted pharmacological interventions, and emerging delivery technologies aimed at enhancing GSH bioavailability and functionality.

5.1. Nutritional supplementation and precursors

One of the most widely used approaches involves the administration of N-acetylcysteine (NAC), a cysteine precursor that enhances endogenous GSH synthesis. Clinical studies have shown that NAC supplementation can reduce irritability, improve social responsiveness, and decrease stereotypic behaviors in children with ASD [21]. NAC not only boosts GSH levels but also provides anti-inflammatory and anti-apoptotic benefits. Other precursors, such as methyl cobalamin (vitamin B12) and folinic acid, support the methionine cycle and transculturation pathway, thereby indirectly promoting GSH biosynthesis [22].

In addition to precursors, oral and intravenous glutathione supplements have been evaluated. While oral GSH is subject to degradation in the gastrointestinal tract, liposomal and sublingual formulations have shown improved absorption and potential clinical benefit [23]. However, the long-term efficacy of oral GSH remains under debate, and parenteral routes are typically more effective for acute GSH repletion.

5.2. Biological agents and redox-modulating therapies

Beyond traditional supplementation, redox-modulating agents such as sulforaphane—a natural compound from broccoli sprouts—have demonstrated potential in improving behavior and oxidative markers in ASD individuals. Sulforaphane activates the Nrf2 pathway, which upregulates GSH-related genes and enhances cellular antioxidant defenses [24]. This mechanism supports endogenous detoxification and inflammation control, aligning with the redox dysregulation hypothesis in ASD.

Additionally, probiotics and microbiome-targeted therapies have been proposed to enhance gut-derived GSH synthesis. Dysbiosis, commonly observed in ASD patients, can impair the production and recycling of GSH. Certain probiotic strains may help restore microbial balance and contribute to systemic antioxidant capacity, though human studies remain limited in this area.

5.3. Clinical studies and evidence of efficacy

Several clinical trials have assessed the impact of GSH-targeting interventions on ASD symptoms. In one open-label trial, GSH supplementation led to improvements in expressive language and attention span in children with ASD, particularly those with low baseline GSH levels [25]. Other trials combining NAC, methyl cobalamin, and folinic acid reported synergistic benefits, suggesting that a multi-nutrient strategy may be more effective than monotherapy [22]. Still, variability in treatment outcomes indicates a need for personalized approaches based on redox biomarkers and genetic profiles.

DOI: 10.54254/2753-8818/2025.AU25169

In summary, therapeutic strategies aimed at enhancing glutathione levels—whether through precursor support, direct supplementation, or pathway activation—have shown promise in reducing oxidative stress and alleviating ASD symptoms. Continued research is needed to optimize dosing, delivery routes, and combinations, as well as to identify patient subgroups most likely to benefit from redox-based therapies.

6. Challenges and future directions

Despite encouraging findings linking glutathione (GSH) dysfunction to autism spectrum disorder (ASD) and the promising results of redox-targeted therapies, several limitations continue to hinder their broader application. One major challenge lies in the heterogeneity of ASD itself. The wide range of symptom presentations, severity, and comorbidities makes it difficult to identify which subgroups are most likely to benefit from GSH-related interventions. Personalized treatment approaches based on redox biomarkers and genetic screening may be necessary but are not yet widely available in clinical settings.

Secondly, limitations in clinical trial design affect the strength of current evidence. Many studies investigating GSH supplementation or related compounds are small-scale, open-label, or lack appropriate placebo controls. Although several trials report positive outcomes, the absence of standardized outcome measures and short follow-up durations raise concerns about reproducibility and long-term efficacy.

Furthermore, the bioavailability and delivery of glutathione remain important technical barriers. Oral GSH has limited absorption unless specially formulated, and intravenous or liposomal delivery methods, while more effective, are costly and less accessible. Ensuring consistent delivery of active GSH across the blood–brain barrier is another ongoing scientific challenge.

Lastly, gaps in mechanistic understanding persist. While existing research has elucidated many of GSH's roles in antioxidant defense, neurotransmission, and methylation, the causal links between these mechanisms and specific ASD behaviors remain incompletely defined. Large-scale, multi-omics studies integrating genomics, metabolomics, and neuroimaging could help clarify these relationships and guide future therapeutic development.

To address these issues, future research should prioritize:

1. Randomized, double-blind, placebo-controlled trials with larger, diverse cohorts.
2. Development of clinically applicable redox-based diagnostic tools.
3. Integration of GSH-based interventions into multidisciplinary ASD treatment models.
4. Exploration of novel delivery systems (e.g., nanocarriers, microbiota-targeted delivery).
5. Ethical considerations and long-term safety monitoring in pediatric applications.

7. Conclusion

Glutathione plays a multifaceted and foundational role in maintaining redox balance, supporting neurotransmitter regulation, and facilitating gene–environment interactions, all of which are central to the pathophysiology of autism spectrum disorder. Substantial evidence indicates that individuals with ASD commonly exhibit decreased GSH levels and increased oxidative stress, linking biochemical imbalance to neurodevelopmental dysfunction.

Through reviewing recent studies, this paper has demonstrated that GSH deficiency is not merely a consequence of ASD but may actively contribute to its onset and progression. Mechanistically, GSH protects mitochondrial function, modulates excitatory neurotransmission, and influences DNA methylation and detoxification. Therapeutically, interventions aimed at restoring GSH—via NAC,

DOI: 10.54254/2753-8818/2025.AU25169

folate-cycle nutrients, liposomal GSH, or redox modulators like sulforaphane—have shown measurable benefit in clinical trials, though further validation is needed.

The importance of glutathione in ASD research lies not only in its therapeutic potential but also in its utility as a biomarker of disease progression and treatment response. As personalized and integrative medicine continues to evolve, GSH-centered strategies may become a cornerstone in managing ASD, especially for subgroups with identifiable redox vulnerabilities.

Future research should continue to explore glutathione's mechanisms, refine delivery approaches, and establish long-term efficacy and safety. With these developments, redox-based therapies may shift from an experimental option to a clinically standard component of ASD care.

References

[1] Bjørklund, G., et al. (2021). The impact of glutathione metabolism in autism spectrum disorder. Pharmacological Research, 166, 105437.
[2] Ghanizadeh, A., et al. (2012). Glutathione-related factors and oxidative stress in autism: A review. Current Medicinal Chemistry, 19(23), 4000–4005.
[3] Chauhan, A., et al. (2012). Brain region-specific glutathione redox imbalance in autism. Neurochemical Research, 37(8), 1681–1689.
[4] Frye, R. E., & James, S. J. (2014). Metabolic pathology of autism in relation to redox metabolism. Biomarkers in Medicine, 8(3), 321–330.
[5] Mandic-Maravic, V., et al. (2021). Glutathione S-Transferase Polymorphisms and Clinical Characteristics in Autism Spectrum Disorders. Frontiers in Psychiatry, 12, 672389.
[6] Delhey, L. M., et al. (2018). Comparison of Treatment for Metabolic Disorders Associated with Autism: Reanalysis of Three Clinical Trials. Frontiers in Neuroscience, 12, 19.
[7] Durieux, A. M. S., et al. (2016). Cortical and subcortical glutathione levels in adults with autism spectrum disorder. Autism Research, 9(4), 429–435.
[8] Kern, J. K., et al. (2011). A clinical trial of glutathione supplementation in autism spectrum disorders. Medical Science Monitor, 17(12), CR677–CR682.
[9] Radwan, K., et al. (2023). An Open-Label Case Series of Glutathione Use for Symptomatic Management in Children with Autism Spectrum Disorder. Medical Sciences, 11(4), 73.
[10] James, S., et al. (2015). Chelation for autism spectrum disorder (ASD). Cochrane Database of Systematic Reviews, 5(5), CD010766.
[11] Bjørklund, G., et al. (2020). The role of glutathione redox imbalance in autism spectrum disorder: A review. Free Radical Biology & Medicine, 160, 149–162.
[12] Frye, R. E., et al. (2014). Redox metabolism and mitochondrial dysfunction in ASD. Biomarkers in Medicine, 8(3), 325–338.
[13] Mandic-Maravic, V., et al. (2021). Genetic polymorphisms in detoxification pathways and ASD severity. Frontiers in Psychiatry, 12, 672389.
[14] Delhey, L. M., et al. (2018). Effects of antioxidant treatment on methylation metabolism in ASD. Frontiers in Neuroscience, 12, 23.
[15] Chauhan, A., et al. (2012). GSH and mitochondrial defense in ASD. Neurochemical Research, 37(8), 1681–1695.
[16] Frye, R. E., & James, S. J. (2014). Glutathione metabolism and neural protection. Biomarkers in Medicine, 8(3), 340–345.
[17] Durieux, A. M. S., et al. (2016). Role of GSH in glutamate regulation in ASD. Autism Research, 9(4), 429–435.
[18] Radwan, K., et al. (2023). Monoamine balance and GSH therapy. Medical Sciences, 11(4), 73.
[19] Delhey, L. M., et al. (2018). GSH in epigenetic and methylation pathways in ASD. Frontiers in Neuroscience, 12, 28.
[20] Mandic-Maravic, V., et al. (2021). GST gene polymorphisms and detox capacity in ASD. Frontiers in Psychiatry, 12, 672389.
[21] James, S., et al. (2015). N-acetylcysteine for irritability in autism. Cochrane Reviews, 5(5), CD010766.
[22] Delhey, L. M., et al. (2018). Combined nutrient therapy in autism. Frontiers in Neuroscience, 12, 19.
[23] Kern, J. K., et al. (2011). Oral and intravenous glutathione: Efficacy and bioavailability. Medical Science Monitor, 17(12), CR677–CR682.

DOI: 10.54254/2753-8818/2025.AU25169

[24] Bjørklund, G., et al. (2020). Sulforaphane and the Nrf2 pathway in autism therapy. Free Radical Biology & Medicine, 160, 149–162.
[25] Radwan, K., et al. (2023). GSH treatment in language and attention symptoms. Medical Sciences, 11(4), 73.